

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413



REF: MDOL/CS-SE/2020-21/021

September 16, 2020

To,

Listing Department

National Stock Exchange of India Limited

"Exchange Plaza", 5th Floor,

Plot No. C-1, Block G,

Bandra - Kurla Complex,

Bandra(E), Mumbai - 400 051

Symbol: MANGALAM

Sub: Un-Audited Financial Results for the Quarter ended June 30, 2020

Dear Sir / Madam,

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), the Company had submitted Un-audited Financial Results for the quarter ended June 30, 2020 along with Limited Review Report of the said period in the prescribed form on Monday, August 10, 2020 vide letter reference no. MDOL/CS-SE/2020-21/015.

We are resubmitting the same Un-audited Financial Results for the quarter ended June 30, 2020 along with Limited Review Report of the said period in the prescribed form with appropriate Signatures / Digital Signatures.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For Mangalam Drugs & Organics Limited



Geeta Karira

Company Secretary & Compliance officer

Un-Audited Financial Results for the Quarter Ended 30th June 2020 approved and taken on record by the Board at their meeting dated 10th August, 2020

		August, 2020		(Rs. In Lacs)	
Sr.No	Particulars	Quarter Ended			Year Ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		Unaudited	Audited	Unaudited	Audited
A) Part-1 Statement of Un-Audited Financial Results for the Quarter Ended June 30, 2020					
1	Revenue from Operations	10,364.06	8,809.46	6,504.23	28,235.36
2	Other Income	65.48	45.33	3.87	118.12
3	Total Revenue(1+2)	10,429.54	8,854.79	6,508.10	28,353.48
4	Expenses				
	(a) Cost of Materials Consumed	6,919.36	5,279.54	4,216.94	17,807.13
	(b) Purchase of Stock in trade	0.00	0.00	0.00	0.00
	(c) Changes in Inventories of, Finished Goods and Stock-in-trade & Work In Progress	383.59	1,084.22	178.08	1,727.66
	(d) Employee Benefits Expenses	686.63	705.66	604.87	2,604.41
	(e) Finance Costs	215.80	246.29	265.13	1,040.47
	(f) Depreciation & amortization expenses	206.10	209.61	179.92	821.78
	(g) Other Expenses	1,012.76	1,024.11	958.85	3,726.81
	Total Expenses	9,424.23	8,549.43	6,403.79	27,728.27
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	1,005.31	305.36	104.31	625.21
6	Exceptional items	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	1,005.31	305.36	104.31	625.21
8	Extraordinary Items	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	1,005.31	305.36	104.31	625.21
10	Tax Expenses				
	Current Tax	185.09	34.69	30.38	110.10
	Less: MAT credit entitlement / reversal	(9.33)	(29.33)	-00	(104.74)
	Deferred Tax	0.00	(205.40)	0.00	(205.40)
11	Net Profit(+)/Loss(-) after Tax (9-10)	829.55	505.40	73.93	825.25
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	(6.99)	0.32	0.52	2.32
13	Total Comprehensive Income	822.56	505.72	74.45	827.57
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity				8,811.05
16	Earnings Per Share (EPS) (of Rs 10/-each)(not annualised):				
	(a) Basic	5.24	3.19	0.47	5.21
	(b) Diluted	5.24	3.19	0.47	5.21

Notes :

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on August 10, 2020. The Statutory Auditors have expressed an unmodified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- Deferred Tax calculation as per Ind AS 12 is considered by the Company on annual basis
- Earlier period figures have been regrouped/ rearranged wherever necessary.

Place/Mumbai
Date: 10th August, 2020

**PARAG
RAMAN
HANGEKAR**
Digitally signed by
PARAG RAMAN
HANGEKAR
Date: 2020.08.10
14:10:52 +05'30'

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd.

(Shri Govardhan M Dhoot)
Chairman & Managing Director
(DIN 01240086)

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Mangalam Drugs and Organics Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**TO THE BOARD OF DIRECTORS OF
Mangalam Drugs and Organics Limited**

We have reviewed the accompanying Statement of unaudited standalone financial results of **Mangalam Drugs and Organics Limited** ("Company") for the quarter ended 30th June, 2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed, under Section 133 of the Companies Act, 2013, and our accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to the financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Basis for Qualified conclusion:

Based on our review and explanation and information provided to us by the Management, deferred tax as per Ind AS 12 is considered on annual basis and hence impact of the same is not ascertainable on the Profit & Loss account and Assets and Liabilities as on 30th June, 2020.



Qualified Conclusion:

Based on our review conducted as above, except for the matter prescribed in the Basis for Qualified Opinion paragraph nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Batliboi & Purohit
Chartered Accountants
Firm Registration No.: 101048W

PARAG
RAMAN
HANGEKAR

Digitally signed by
PARAG RAMAN
HANGEKAR
Date: 2020.08.10
14:05:08 +05'30'



Parag Hangekar
Partner
Membership No: 110096
UDIN: 20110096AAAACS3345

Date: August 10, 2020
Place: Mumbai